GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a comparison of gene expression profile in unsorted bone marrow (BM) samples from patients with multiple myeloma (MM), acute leukemia, and diffuse large B-cell lymphoma infiltrating the BM, the leading myeloma distinguishing gene was GPRC5D. This gene was highly expressed in BM samples from the 10 MM cases examined as opposed to minimal expression in samples from the eight cases with other hematological malignancies. Moreover, following antimyeloma treatment the expression of GPRC5D decreased several folds. The strong and selective expression of GPRC5D in MM cells makes this gene and its encoded surface protein as promising markers for monitoring the tumor load and hopefully also as targets for antimyeloma antibodies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [21]
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [21]
Citations
Cites
Paiva, B., Martinez-Lopez, J., Vidriales, M.-B., Mateos, M.-V., Montalban, M.-A., Fernandez-Redondo, E., Alonso, L., Oriol, A., Teruel, A.-I., de Paz, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1967 · Cited by 233
Atamaniuk, J., Gleiss, A., Porpaczy, E., Kainz, B., Grunt, T. W., Raderer, M., Hilgarth, B., Drach, J., Ludwig, H., Gisslinger, H., et al. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02679.x · Cited by 128
CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
Benson, D. M., & Byrd, J. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4061 · Cited by 23
Pilarski, L. M., Baigorri, E., Mant, M. J., Pilarski, P. M., Adamson, P. J., Zola, H., & Belch, A. R. (2008) · Clinical medicine Oncology · doi:10.4137/cmo.s615 · Cited by 21
Niche-modulated and niche-modulating genes in bone marrow cells
Cohen, Y., Garach‐Jehoshua, O., Bar‐Chaim, A., & Kornberg, A. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.42 · Cited by 7
Self-citation
Research works printed but not linked: 1
- Pilarski LM, 2008, Clin Med Oncol., 2, 275
Cited by
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
GPRC5D-Targeted CAR T Cells for Myeloma
Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209900 · Cited by 411
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391
“Earlier work discovered GPRC5D expression in two anatomic locations: the hair follicle (14–16), considered an immune-privileged site (17–19), and the bone marrow from patients with MM (20, 21).”
BackgroundVerkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003805 · Cited by 182
“9) Unknown, n (%) 1 (8) 2 (12) 9 (60) M protein, n (%) IgG 7 (58) 13 (76) 9 (60) IgA 2 (17) 3 (18) 3 (20) FLC only 3 (25) 1 (6) 2 (13) Nonsecretor 0 0 1 (7) Unknown 1 (8) 0 0 ISS score, n (%) 1 6 (50) 2 4 (33) 3 2 (17) Unknown 1 (8) High-risk cytogenetics,* n (%) 1 (8) 6 (38) 3 (33) Unknown 0 1 (6) 6 (40) del (17p) 0…”
InfluentialZhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., Wang, D., Luo, X., Cui, J., Huang, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00372-6 · Cited by 166
Metadata
- Authors
- Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A., & Kornberg, A.
- Affiliations
- Tel Aviv University (IL)
- Hematology LaboratoryAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel
- Corresponding author
- Cohen, Yossi
- Venue
- Hematology
- Publisher
- Informa UK Limited
- Published
- 2013-11
- Volume
- 18
- Issue
- 6
- Pages
- 348-351
- ISSN
- 1024-5332 (ISSN-L)
- 1607-8454
- OpenAlex
- W2011876556
- Cited by
- 54
- References
- 5
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 12 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 1 · 2017: 1 · 2014: 1
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hematology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agilent Technologies
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- GPRC5D, multiple myeloma, bone marrow, gene expression profiling, hematologic malignancies, acute leukemia, diffuse large B-cell lymphoma, therapeutic target, monoclonal antibodies, minimal residual disease
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Multiple Myeloma, Biomarkers, Tumor, Receptors, G-Protein-Coupled, Tumor Burden, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. https://app.cochat.ai/papers/10.1179/1607845413y.0000000079
- The paper
- Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A., & Kornberg, A. (2013). GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. https://doi.org/10.1179/1607845413y.0000000079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.